Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
about
A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome coreLigand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity.Anticancer activity of methyl-substituted oxaliplatin analogs.Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocyclesInhibitory effect of platinum and ruthenium bipyridyl complexes on porcine pancreatic phospholipase A2.The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivoFighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies.Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.Anticancer activity of metal complexes: involvement of redox processes.Targeted and multifunctional arene ruthenium chemotherapeutics.The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.In vitro characterization of a novel C,N-cyclometalated benzimidazole Ru(II) arene complex: stability, intracellular distribution and binding, effects on organic osmolyte homeostasis and induction of apoptosis.Modulation of the Aβ peptide aggregation pathway by KP1019 limits Aβ-associated neurotoxicity.Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potential.Modulation of activity of known cytotoxic ruthenium(III) compound (KP418) with hampered transmembrane transport in electrochemotherapy in vitro and in vivo.Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells.Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells.Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse.X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019).EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae.A shotgun metalloproteomic approach enables identification of proteins involved in the speciation of a ruthenium anticancer drug in the cytosol of cancer cells.Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS.Aquation Is a Crucial Activation Step for Anticancer Action of Ruthenium(II) Polypyridyl Complexes to Trigger Cancer Cell Apoptosis.Solution equilibria and antitumor activities of pentamethylcyclopentadienyl rhodium complexes of picolinic acid and deferiproneThe Spectroscopic and Conductive Properties of Ru(II) Complexes with Potential Anticancer PropertiesAnticancer Activities of Mononuclear Ruthenium(II) Coordination Complexes
P2860
Q27666776-DFE4A386-D117-4383-ABF2-CB390AF51509Q27682260-5D3CB05A-4753-4EAB-AC79-3B063F9A2D12Q30515979-949CB1A2-10C8-4990-B864-097151397739Q30623124-8CD7D7FC-8487-4A7B-B375-1DC5E71259A0Q34016733-F3A15915-8B3B-4796-9799-E0A7FB1D46A2Q37253610-908FB85D-3853-4357-9AFE-323341F31436Q37337277-E1774A43-59E2-4535-BA6E-39A6F75E427EQ37657640-8E662C9E-F5EA-4588-B927-86DFBBFE6E23Q37833099-F75D30C6-06F2-4EFC-A5C7-E77B00415F4DQ37920741-BF1FC085-04DA-41D8-97B1-6346CBFB5F35Q38096196-C410D277-4D21-4704-96B8-59D14B88DC3EQ38105454-C943A09C-0DE8-40DE-9E62-6AC09B8E2B6DQ38720938-2B0CA2C2-D811-4450-8963-BDBE0115D6C4Q38895597-7715D6F7-C01E-4764-B777-A1F849B939F5Q38941268-919753F7-F34D-4106-A882-E6DE7898AB98Q38941379-EE79EE95-C646-40EB-9129-ED81ECF18C70Q38981930-25FE8950-ECAA-49C1-B39D-69A2DDF30A30Q39265638-53AF4397-F5CC-440E-BFAF-974AA44CA49EQ39294174-BD12DC8D-39EE-4396-8F21-BAA6C95FFACCQ39576903-AEE61F53-B3A3-4E0B-8A49-D7DAE2F8C9B4Q39773916-0BAC2805-38C3-4C21-A1D9-F36422ABB2A6Q41883625-D8CDAE2B-8426-4A5C-BB9D-DA63F76774D4Q43242098-1D324A0A-33C5-4032-B569-02C94335952AQ43811304-0FCAE9B7-C52A-496D-AD69-FF1EEA4769AAQ44384757-9C892C3C-6B23-42D0-A450-7CED809C20EEQ46750665-60C93469-4409-4FE9-8724-AF818113464FQ50063144-2B7EEABD-D3AB-419D-BB34-3BD968AC2665Q53116557-27B326E7-0180-49C2-9F07-03D8A40A1739Q53463488-4FBFE364-1DCA-441A-9EC6-A748F57A8677Q58572094-A9A6D992-86E2-4733-BA7B-5BC148BC7BD2Q59062348-1196CA89-390E-4E35-A3BA-196B1A2CD750Q59101621-5BA6F4E5-0F73-433C-9732-52DDAB03644B
P2860
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Intracellular protein binding ...... enium drugs KP1019 and KP1339.
@en
Intracellular protein binding ...... enium drugs KP1019 and KP1339.
@nl
type
label
Intracellular protein binding ...... enium drugs KP1019 and KP1339.
@en
Intracellular protein binding ...... enium drugs KP1019 and KP1339.
@nl
prefLabel
Intracellular protein binding ...... enium drugs KP1019 and KP1339.
@en
Intracellular protein binding ...... enium drugs KP1019 and KP1339.
@nl
P2093
P2860
P50
P1476
Intracellular protein binding ...... enium drugs KP1019 and KP1339.
@en
P2093
Bihter Atil
Caroline Bartel
Katharina Böck
Michael Micksche
Mir Ali Reza Hoda
Wilfried Körner
P2860
P2888
P304
P356
10.1007/S00775-010-0642-1
P577
2010-03-11T00:00:00Z